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To the Editor:
“Addressing the Obesity Epidemic: A Genomics 
Perspective” in your April 2007 (1) issue speaks of 
the importance of considering all aspects of obesity. 
However, one aspect overlooked in the article is weight 
gain associated with medical treatment. Many classes 
of drugs are associated with weight gain that leads to 
overweight or obesity; these include atypical antipsy-
chotic drugs, lithium, some antidepressant drugs, some 
antiepileptic drugs, and some steroids. Other drugs are 
associated with fat redistribution (e.g., some drugs for 
HIV/AIDS).
In addition to increasing weight, atypical antipsychotic 
drugs increase risk for hyperglycemia (as noted in a black-
box label required by the Food and Drug Administration 
[FDA]), and they are associated with lipid dysregula-
tion (2). Atypical antipsychotic drugs induce excitation 
and hypomania or mania, adverse effects never reported 
for the older versions of typical antipsychotic drugs 
(3). Some atypical antipsychotic drugs are also noncardiac 
QTc-interval–prolonging drugs and are associated with 
increased sudden cardiac death (4).   
Atypical antipsychotic drugs are widely used off-
label. The FDA issued a Public Health Advisory warn-
ing of a 60% to 70% increased risk for mortality among 
elderly people with dementia being treated with atypical 
antipsychotic medications (5). From 1993 through 2002, 
prescriptions for atypical antipsychotic drugs for Ameri-
can children increased 500% (all off-label); 85% of those 
prescriptions were for nonpsychotic conditions (6). The 
public health implications of wide off-label use of this class 
of drugs merits more study.
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